Economic Evaluation of Treatments for Advanced Melanoma

Economic evaluation of treatments for advanced melanoma examines both the costs incurred by healthcare systems and the health gains achieved through novel therapies. Historically, standard cytotoxic agents offered limited survival benefit at modest cost, but the advent of targeted BRAF inhibitors and immune checkpoint inhibitors has transformed clinical outcomes while introducing substantial expense. Key components of economic analysis include estimation of direct medical costs—drug acquisition, administration, monitoring and management of adverse events—alongside measurement of patient benefits in terms of quality-adjusted life years (QALYs). Methodological approaches range from Markov state-transition models to partitioned-survival modelling, accommodating long-term extrapolation beyond trial durations. Analyses are conducted from various perspectives (payer, societal) and incorporate willingness-to-pay thresholds to determine incremental cost-effectiveness ratios (ICERs). Global evaluations reveal marked variation in pricing and healthcare resource utilisation, with studies demonstrating that immune checkpoint inhibitors may achieve cost-effectiveness under certain thresholds and in specific healthcare settings, while targeted therapies often exceed conventional willingness-to-pay limits unless drug prices are reduced or durable responses are confirmed. Economic studies also emphasise the financial impact of managing grade 3–4 toxicities, adherence to follow-up guidelines and patient selection strategies to optimise value. These analyses inform reimbursement decisions, guide clinical practice, and shape policy to ensure sustainable access to high-cost but potentially life-extending treatments worldwide.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Economic Evaluation of Treatments for Advanced Melanoma publication trend

The graph below shows the total number of articles in economic evaluation of treatments for advanced melanoma across all publications each year (not limited to Nature Index journals).

Technical terms

Quality-adjusted life year (QALY): Composite metric combining duration and quality of life into a single utility-weighted measure.

Incremental cost-effectiveness ratio (ICER): Ratio of difference in costs to difference in effectiveness (usually QALYs) between two interventions.

Markov model: Simulation framework dividing disease progression into discrete health states with transition probabilities over time.

Partitioned-survival model: Approach using survival curves for progression-free, post-progression and overall survival to allocate patient time across health states.

Health state utility: Numerical preference value (0–1) representing quality of life in a specific health condition, used to weight QALYs.

References

1. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. The European Journal of Health Economics (2018).
2. Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong. Cost Effectiveness and Resource Allocation (2020).
3. Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma. PLOS ONE (2014).
4. Economic burden of toxicities associated with treating metastatic melanoma in eight countries. The European Journal of Health Economics (2015).